2-hydroxyglutaric acid

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 1586 references associated with 2-hydroxyglutaric acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 2-hydroxyglutaric acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-hydroxyglutaric acid

MeSH term MeSH ID Detail
Metabolic Diseases D008659 12 associated lipids
Phenylketonurias D010661 7 associated lipids
Hyperoxaluria D006959 3 associated lipids
Canavan Disease D017825 2 associated lipids
Tyrosinemias D020176 2 associated lipids
Total 5

PubChem Associated disorders and diseases

PubChem Biomolecular Interactions and Pathways

NCBI Entrez Crosslinks

All references with 2-hydroxyglutaric acid

Download all related citations
Per page 10 20 50 100 | Total 448
Authors Title Published Journal PubMed Link
Heux S et al. Cofactor engineering in Saccharomyces cerevisiae: Expression of a H2O-forming NADH oxidase and impact on redox metabolism. 2006 Metab. Eng. pmid:16473032
D'Alò F et al. Similarities and differences between therapy-related and elderly acute myeloid leukemia. 2011 Mediterr J Hematol Infect Dis pmid:22220249
Chaturvedi A et al. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. 2017 Leukemia pmid:28232670
Chaturvedi A et al. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. 2016 Leukemia pmid:27063596
Tefferi A et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. 2012 Leukemia pmid:21912393
Tefferi A et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. 2010 Leukemia pmid:20508616
Patnaik MM et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. 2010 Leukemia pmid:20485371
Tefferi A Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. 2010 Leukemia pmid:20428194
Pollyea DA et al. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. 2013 Leuk. Lymphoma pmid:22680765
Kim H et al. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists. 2016 Sep-Oct Korean J Radiol pmid:27587950